Welcome to our dedicated page for Immunogen news (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on Immunogen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunogen's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ImmunoGen, Inc. (NASDAQ: IMGN) announced the appointment of Isabel Kalofonos as Senior Vice President and Chief Commercial Officer. This move comes at a pivotal time following the November approval of ELAHERE for platinum-resistant ovarian cancer. CEO Mark Enyedy emphasized Kalofonos's extensive experience in global commercialization will enhance their launch execution and drive ELAHERE's market adoption. Previously, she helped launch a drug at Galderma and led the TAKHZYRO launch at Takeda Pharmaceuticals.
Kalofonos expressed enthusiasm for the role, citing strong physician reception for ELAHERE and the company's ambitions to expand its portfolio. ImmunoGen aims to establish ELAHERE as standard care and broaden its impact in Europe.
ImmunoGen Inc. (NASDAQ: IMGN) announced a conference call scheduled for April 28, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 operating results. The call will also include a business update from management. Interested parties can access the call through registration, and a replay will be available on the company’s website afterward. ImmunoGen specializes in developing antibody-drug conjugates (ADCs) aimed at improving outcomes for cancer patients, focusing on targeted therapies that enhance anti-tumor activity and tolerability.
ImmunoGen, Inc. has secured a term loan financing facility worth $175 million with Pharmakon Advisors, LP. The initial draw of $75 million will be executed immediately upon agreement, while an additional $50 million can be accessed based on positive results from its MIRASOL trial for ELAHERE™. The latter can potentially increase to $100 million through mutual agreement. The facility will feature a five-year term with interest-only payments for the first 36 months. This agreement aims to bolster ImmunoGen's balance sheet and support growth in its ADC pipeline. CEO Mark Enyedy emphasized the importance of this non-dilutive capital in advancing their oncology initiatives.